

Freedom of Information Request: Our Reference CTMUHB_291_22

You asked:

Q1. How many patients were treated in last 4 months by the Dermatology department (for any disease) with each of the following:

- Abrocitinib
- Acitretin
- Alitretinoin
- Azathioprine
- Baricitinib
- Ciclosporin
- Dupilumab
- Methotrexate
- Mycophenolate mofetil
- Pimecrolimus
- Tacrolimus ointment
- Tralokinumab
- Upadacitinib

Please see provided below a table populated with the data that Medicines Management are able to provide in relation to question 1.

Table A relates to the number of patients treated by Secondary Care within Dermatology for the period of 1st April 2022 to 31st July 2022, the latest 4 months available.

Table B relates to the number of items issued in Primary Care for any specialty for the period of 1st February 2022 to the 31st May 2022, the latest 4 months available. Unfortunately, we are unable to provide patient numbers or specific specialties for Primary Care data, as we do not hold these details.

Table A

Medicine	Number of Patients
Abrocitinib	0
Acitretin	83
Alitretinoin	5
Azathioprine	7
Baricitinib	4
Ciclosporin	13
Dupilumab	71
Methotrexate	57

Mycophenolate mofetil	5
Pimecrolimus	0
Tacrolimus ointment	6
Tralokinumab	0
Upadacitinib	0

Table B

Description	Number of Items
Methotrexate_Tab 2.5mg	5,593
Azathioprine 50mg Tablets	1,493
Azathioprine 25mg Tablets	364
Tacrolimus_Oint 0.1%	125
Methotrexate_Inj 20mg/0.4ml Pf Dev	112
Methotrexate_Tab 10mg	108
Methotrexate_Inj 15mg/0.3ml Pf Dev	48
Tacrolimus_Oint 0.03%	46
Methotrexate_Inj 20mg/0.8ml Pf Pen	41
Ciclosporin_Eye Dps 0.1% 0.3ml Ud	36
Acitretin 10mg Capsules	34
Baricitinib_Tab 4mg	28
Methotrexate_Inj 10mg/0.2ml Pf Dev	26
Pimecrolimus_Crm 1%	26
Methotrexate_Inj 15mg/0.6ml Pf Pen	23
Methotrexate_Inj 7.5mg/0.15ml Pf Dev	15
Methotrexate_Inj 10mg/0.4ml Pf Pen	10
Ciclosporin_Cap 100mg	9
Methotrexate_Inj 17.5mg/0.35ml Pf Dev	8
Methotrexate_Inj 7.5mg/0.3ml Pf Pen	7
Acitretin 25mg Capsules	6
Ciclosporin (eye Anti Inflam)	6
Azathioprine_Liq Spec 50mg/5ml	5
Ciclosporin_Cap 50mg	5
Methotrexate_Inj 22.5mg/0.45ml Pf Dev	5
Methotrexate_Inj 25mg/0.5ml Pf Dev	5
Alitretinoin 30mg Capsules	4
Azathioprine_Oral Susp 50mg/5ml	4
Ciclosporin_Eye Oint 0.2%	4
Methotrexate_Inj 17.5mg/0.7ml Pf Pen	4
Methotrexate_Oral Soln 2mg/ml S/f	4
Tacrolimus_Liq Spec 5mg/5ml	4
Baricitinib_Tab 2mg	3
Methotrexate_Inj 12.5mg/0.5ml Pf Pen	3
Methotrexate_Inj 20mg/0.4ml Pfs	3
Methotrexate_Inj 25mg/1ml Pf Pen	3

Azathioprine_Oral Susp 20mg/5ml	2
Azathioprine_Oral Susp 25mg/5ml	1
Ciclosporin_Eye Dps 0.05% 0.4ml Ud P/f	1
Ciclosporin_Eye Oint 0.2% P/f	1
Methotrexate_Inj 22.5mg/0.9ml Pf Pen	1
Methotrexate_Inj 25mg/0.5ml Pfs	1
Methotrexate_Inj 25mg/1ml Pfs	1
Methotrexate_Inj 7.5mg/0.3ml Pfs	1
Tacrolimus_Cap 1mg	1
Tacrolimus_Tab 4mg M/r	1

Q2. Of the patients treated in the last 4 months with any of the products listed in Q1, how many patients were paediatric (age 17 or under)?

Patient level details (age) are not captured on our Medicines Management system.

The detailed information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

Q3. How many patients were treated in the last 4 months with phototherapy (UVB or PUVA) for atopic dermatitis ONLY?

We can confirm that the Health Board does not centrally record this information by skin condition. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

However, in order to fulfil our obligation under Section 16 of the Act to provide advice and assistance, we can confirm that 217 patients were treated in the last 4 months with phototherapy.